News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
197,650 Results
Type
Article (9013)
Company Profile (124)
Press Release (188508)
Multimedia
Podcasts (83)
Webinars (12)
Section
Business (58325)
Career Advice (381)
Deals (10534)
Drug Delivery (35)
Drug Development (35759)
Employer Resources (77)
FDA (3255)
Job Trends (4691)
News (105621)
Policy (7485)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (1)
2027 Pharm Country Standard (1)
Academia (383)
Accelerated approval (8)
Adcomms (6)
Allergies (51)
Alliances (13618)
ALS (63)
Alzheimer's disease (503)
Antibody-drug conjugate (ADC) (157)
Approvals (3436)
Artificial intelligence (178)
Autoimmune disease (78)
Automation (11)
Bankruptcy (65)
Best Places to Work (3634)
BIOSECURE Act (16)
Biosimilars (107)
Biotechnology (82)
Bladder cancer (44)
Brain cancer (23)
Breast cancer (180)
Cancer (1990)
Cardiovascular disease (135)
Career advice (350)
Career pathing (28)
CAR-T (190)
CDC (13)
Cell therapy (417)
Cervical cancer (10)
Clinical research (31623)
Collaboration (712)
Compensation (653)
Complete response letters (23)
COVID-19 (851)
CRISPR (23)
C-suite (396)
Cystic fibrosis (39)
Data (2715)
Decentralized trials (1)
Denatured (13)
Depression (62)
Diabetes (135)
Diagnostics (787)
Digital health (10)
Diversity (8)
Diversity, equity & inclusion (21)
Drug discovery (67)
Drug pricing (63)
Drug shortages (3)
Duchenne muscular dystrophy (67)
Earnings (26277)
Editorial (40)
Employer branding (10)
Employer resources (67)
Events (39786)
Executive appointments (462)
FDA (4413)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (2)
Frontotemporal dementia (6)
Funding (491)
Gene editing (53)
Generative AI (18)
Gene therapy (175)
GLP-1 (338)
Government (948)
Grass and pollen (2)
Guidances (145)
Healthcare (3068)
HIV (26)
Huntington's disease (13)
IgA nephropathy (21)
Immunology and inflammation (93)
Immuno-oncology (39)
Indications (43)
Infectious disease (920)
Inflammatory bowel disease (76)
Inflation Reduction Act (8)
Influenza (22)
Intellectual property (89)
Interviews (62)
IPO (6214)
IRA (19)
Job creations (1103)
Job search strategy (272)
JPM (36)
Kidney cancer (11)
Labor market (74)
Layoffs (189)
Leadership (28)
Legal (995)
Liver cancer (34)
Longevity (2)
Lung cancer (295)
Lymphoma (260)
Machine learning (18)
Management (23)
Manufacturing (342)
MASH (104)
Medical device (815)
Medtech (819)
Mergers & acquisitions (4842)
Metabolic disorders (466)
Multiple sclerosis (80)
NASH (8)
Neurodegenerative disease (94)
Neuropsychiatric disorders (34)
Neuroscience (971)
NextGen: Class of 2026 (1167)
Non-profit (317)
Now hiring (52)
Obesity (217)
Opinion (191)
Ovarian cancer (65)
Pain (60)
Pancreatic cancer (72)
Parkinson's disease (77)
Partnered (4)
Patents (157)
Patient recruitment (205)
Peanut (19)
People (19070)
Pharmaceutical (37)
Pharmacy benefit managers (7)
Phase 1 (9990)
Phase 2 (14594)
Phase 3 (10386)
Pipeline (2257)
Policy (135)
Postmarket research (581)
Preclinical (3765)
Press Release (25)
Prostate cancer (69)
Psychedelics (21)
Radiopharmaceuticals (138)
Rare diseases (303)
Real estate (1331)
Recruiting (34)
Regulatory (7197)
Reports (31)
Research institute (444)
Resumes & cover letters (45)
RNA editing (4)
RSV (26)
Schizophrenia (103)
Series A (80)
Series B (60)
Service/supplier (4)
Sickle cell disease (30)
Special edition (24)
Spinal muscular atrophy (49)
Sponsored (7)
Startups (1091)
State (1)
Stomach cancer (2)
Supply chain (25)
Tariffs (47)
The Weekly (69)
Vaccines (305)
Venture capital (49)
Weight loss (96)
Women's health (21)
Worklife (15)
Date
Today (56)
Last 7 days (228)
Last 30 days (841)
Last 365 days (12118)
2026 (1242)
2025 (12180)
2024 (13945)
2023 (15750)
2022 (18016)
2021 (19730)
2020 (16822)
2019 (11282)
2018 (8117)
2017 (9849)
2016 (8162)
2015 (10344)
2014 (7658)
2013 (5577)
2012 (5394)
2011 (5422)
2010 (5273)
Location
Africa (216)
Alabama (22)
Alaska (1)
Arizona (29)
Arkansas (2)
Asia (15850)
Australia (1770)
California (4749)
Canada (907)
China (793)
Colorado (164)
Connecticut (189)
Delaware (185)
Europe (29153)
Florida (619)
Georgia (129)
Hawaii (1)
Idaho (5)
Illinois (256)
India (23)
Indiana (144)
Iowa (14)
Japan (188)
Kansas (74)
Kentucky (11)
Louisiana (1)
Maine (3)
Maryland (492)
Massachusetts (3629)
Michigan (53)
Minnesota (151)
Mississippi (2)
Missouri (36)
Montana (2)
Nebraska (6)
Nevada (18)
New Hampshire (10)
New Jersey (1508)
New Mexico (9)
New York (1431)
North Carolina (577)
North Dakota (1)
Northern California (2500)
Ohio (122)
Oklahoma (7)
Oregon (13)
Pennsylvania (845)
Puerto Rico (13)
Rhode Island (13)
South America (265)
South Carolina (6)
Southern California (1815)
Tennessee (24)
Texas (549)
United States (16081)
Utah (94)
Virginia (92)
Washington D.C. (24)
Washington State (350)
West Virginia (1)
Wisconsin (22)
197,650 Results for "tc biopharm".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
October 15, 2025
·
5 min read
TC BioPharm to Present at the Sequire Investor Summit
TC BioPharm today announced its participation at the upcoming Sequire Investor Summit 2024 scheduled for January 23-25, 2024.
January 18, 2024
·
2 min read
TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds
TC BioPharm plc announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,750,000 of the Company’s American Depositary Shares originally issued in December 2023 with an exercise price of £1.5814 per ADS and a term of five years.
May 6, 2024
·
4 min read
Deals
TC BioPharm Announces Pricing of $3.5 Million Public Offering
TC BioPharm today announced the pricing of a public offering of 1,750,000 of its American Depositary Shares.
December 19, 2023
·
4 min read
Deals
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies
TC BioPharm PLC announced the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell therapies for the treatment of refractory cancers and solid tumors.
May 6, 2024
·
5 min read
Deals
TC BioPharm Announces Closing of $3.5 Million Public Offering
TC BioPharm today announced the closing of its previously announced public offering of 1,750,000 of its American Depositary Shares.
December 22, 2023
·
4 min read
TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe
TC BioPharm PLC announced that CEO, Bryan Kobel and Process Development Manager, Dr. Lauren Bor will be featured “Expert Speakers” at the 7th 7th CAR-TCR Summit Europe, February 27-29th in London, UK.
February 15, 2024
·
1 min read
TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement
TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced that on January 2, 2024, the Company received a written notice from The Nasdaq Stock Market.
January 4, 2024
·
2 min read
TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results
TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announces today that the Company has successfully completed its Safety Cohort and received positive review from the Data Safety Monitoring Board (DSMB).
November 14, 2023
·
3 min read
TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies
TC BioPharm today announced that the Company is undertaking a series of initiatives to reduce costs and drive efficiency in order to reduce cash burn and expand its financial runway.
January 3, 2024
·
3 min read
1 of 19,765
Next